Q1 Earnings Estimate for ELDN Issued By Leerink Partnrs

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($0.28) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.30) EPS and Q4 2025 earnings at ($0.29) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its earnings results on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the prior year, the business posted ($1.00) EPS.

Separately, Guggenheim started coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Stock Down 3.9 %

Shares of ELDN stock opened at $3.47 on Tuesday. Eledon Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $5.54. The stock has a market cap of $207.29 million, a PE ratio of -1.73 and a beta of 0.80. The business has a 50-day simple moving average of $4.15 and a 200-day simple moving average of $3.89.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock worth $33,000 after acquiring an additional 6,412 shares during the last quarter. Alpine Global Management LLC acquired a new stake in Eledon Pharmaceuticals during the 4th quarter worth $56,000. ADAR1 Capital Management LLC purchased a new stake in shares of Eledon Pharmaceuticals during the fourth quarter worth $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at about $76,000. Finally, Virtu Financial LLC purchased a new position in shares of Eledon Pharmaceuticals in the fourth quarter worth about $82,000. 56.77% of the stock is owned by institutional investors and hedge funds.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).